FOXO3 and liver cancer: In a mouse xenograft model, METTL3 deletion significantly enhanced the resistance of liver cancer to sorafenib by disrupting the METTL3-mediated stability of FOXO3 mRNA, while FOXO3 overexpression restored the sensitivity of liver tumours to sorafenib.